Prospective study of the efficacy and safety of operatable esophageal carcinoma treated with neoadjuvant PD-1 blockade combined with TP regimen

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027455

Enrollment

Unknown

Registered

2019-11-14

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

experimental group:neoadjuvant PD-1 blockade combined with TP regimen

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. Patients with esophageal squamous cell carcinoma diagnosed by histology, stage I, II or IIIA operatable esophageal carcinoma; 3. ECOG PS score is 0-1; 4. The blood routine and biochemical indicators are basically normal, and ECG is basically normal.White blood cell count >= 2,000 / mm3, central granulocyte count >= 1000 / mm3, platelet count >= 100,000 / mm3, hemoglobin >= 9 g / dL, creatinine = 92%.

Exclusion criteria

Exclusion criteria: 1. Immunodeficiency, ongoing systemic immunosuppressive therapy, active autoimmune or infectious disease, and clinically significant concurrent cancer, allergies, chemotherapy or anti-tumor therapy, and other types of malignant tumors; 2. Previously received immunotargeting therapy; 3. Pregnant or lactating women; 4. Suffering from interstitial pneumonia, chronic hepatitis and AIDS; 5. Received other types of immune therapy in the last four weeks.

Design outcomes

Primary

Measure	Time frame
pathologic complete response;ORR;	—

Countries

China

Contacts

Public ContactXiaofang Dai

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

2003xh1047@hust.edu.cn+86 13707127709

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026